DIA President Ling Su On Bridging Gaps In China On The Road To Innovation: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
DIA President Ling Su has a unique perspective on the Chinese market, having served in senior R&D positions with industry – most recently at Novartis China – and as a regulator, including stints in China’s Ministry of Health and as a visiting scientist with U.S. FDA. He recently sat down with PharmAsia News to discuss innovation and the evolution taking place in China.